KalVista Pharmaceuticals, Inc.

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP
483497103
SEDOL
BD06CS0
CIK
0001348911
www.kalvista.com
LEI:
©
FIGI: BBG0026ZG5B0
KALV
KalVista Pharmaceuticals, Inc.
GICS: - · Sector: Healthcare · Sub-Sector: Biotechnology
AI
PROFILER
NAME
KalVista Pharmaceuticals, Inc.
ISIN
US4834971032
TICKER
KALV
MIC
XNAS
REUTERS
KALV.OQ
BLOOMBERG
KALV US
BUILD THEMEFOLIO SHARE IDEAS DISCUSS
LEVERAGE INVEST
EN 728x90
Financial Intelligence
360° iHub Crowd iFeed ATH Tracker Index Tracker ETF TF Spicy2 X-Billboard
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Mon, 16.12.2024       KalVista Pharmaceuticals
US4834971032

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Jeb Ledell has joined the Company as Chief Operating Officer (COO). Mr. Ledell is an accomplished public company COO with a track record of driving operational excellence and strategic growth within the biotechnology industry. “I am pleased to welcome Jeb to KalVista at this key...
Read More
KalVista Pharmaceuticals
Technical Analysis Termsheet Terminal
Permalink
Thu, 05.12.2024       KalVista Pharmaceuticals
US4834971032

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today released financial results for the second fiscal quarter ended October 31, 2024. The Company also provided an operational update, highlighted by the U.S. Food and Drug Administration (FDA) acceptance of a New Drug Application (NDA) for sebetralstat, a novel, investigational treatment for heredit...
Read More
KalVista Pharmaceuticals
Technical Analysis Termsheet Terminal
Permalink
Wed, 04.12.2024       KalVista Pharmaceuticals
US4834971032

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted five newly-hired employees inducement options to purchase an aggregate of 36,000 shares of KalVista common stock on December 2, 2024 as inducements material to each employee entering into employment with KalVista....
Read More
KalVista Pharmaceuticals
Technical Analysis Termsheet Terminal
Permalink
Tue, 26.11.2024       KalVista Pharmaceuticals
US4834971032

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Laurence Reid, Ph.D., has been appointed to the Company’s Board of Directors, effective immediately. Dr. Reid brings more than three decades of experience with a track record of leadership and company-building success. “I am pleased to welcome Dr. Reid, with his deep expertise i...
Read More
KalVista Pharmaceuticals
Technical Analysis Termsheet Terminal
Permalink
Tue, 12.11.2024       KalVista Pharmaceuticals
US4834971032

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at each of the following investor conferences: Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, at 9:10 a.m. EST Jefferies London Healthcare Conference on Thursday, November 21, 2024, at 11:00 a.m. GMT Each p...
Read More
KalVista Pharmaceuticals
Technical Analysis Termsheet Terminal
Permalink
Tue, 05.11.2024       KalVista Pharmaceuticals
US4834971032

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted twelve newly-hired employees inducement options to purchase an aggregate of 78,000 shares of KalVista common stock on November 1, 2024 as inducements material to each employee entering into employment with KalVist...
Read More
KalVista Pharmaceuticals
Technical Analysis Termsheet Terminal
Permalink
Mon, 04.11.2024       KalVista Pharmaceuticals
US4834971032

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) (“KalVista”) today announced the pricing of an underwritten offering of 5,500,000 shares of its common stock at a price of $10.00 per share to certain investors (the “Offering”). The gross proceeds to KalVista from the Offering are expected to be $55 million, before deducting underwriting discounts, co...
Read More
KalVista Pharmaceuticals
Technical Analysis Termsheet Terminal
Permalink
Mon, 04.11.2024       KalVista Pharmaceuticals
US4834971032

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) (“KalVista”), today announced the closing of a synthetic royalty financing agreement with DRI Healthcare Trust (“DRI”) for up to $179 million, comprised of a $100 million upfront payment, a one-time $22 million optional payment upon U.S. product approval, and up to $57 million in a sales-based mileston...
Read More
KalVista Pharmaceuticals
Technical Analysis Termsheet Terminal
Permalink
Mon, 28.10.2024       KalVista Pharmaceuticals
US4834971032

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the presentation of new sebetralstat data at the American College of Allergy Asthma and Immunology (ACAAI) taking place in Boston, MA from October 24 - 28, 2024. Tim Craig, DO, Professor, Departments of Medicine and Pediatrics, Division of Pulmonary, Allergy and Critical Care Medicine...
Read More
KalVista Pharmaceuticals
Technical Analysis Termsheet Terminal
Permalink
Fri, 18.10.2024       KalVista Pharmaceuticals
US4834971032

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that five abstracts have been accepted for e-Poster presentation at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), taking place in Boston, MA from October 24-28. Presentations include: Patient-Reported Anxiety Impacts Utilizati...
Read More
KalVista Pharmaceuticals
Technical Analysis Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S